Johnson & Johnson

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2025-12-16 pm EST			5-day change	1st Jan Change
209.30 ^USD	-2.27%		+4.67%	+44.72%

Dec. 16	S&P Global Appoints Hubert Joly to the Board of Directors and Member of Audit and Compensation and Leadership Development Committees, Effective January 2, 2026	CI
Dec. 15	The Hain Celestial Group, Inc. Appoints Alison E. Lewis as President, Effective December 15, 2025	CI

J&J Expects Tariffs to Cost Company $400 Million

Published on 04/15/2025 at 11:06 am EDT - Modified on 04/15/2025 at 11:30 am EDT

MT Newswires

Johnson & Johnson

-2.27%

Johnson & Johnson (JNJ) is holding its earnings outlook steady despite President Donald Trump signaling he could put tariffs on the pharmaceutical industry. The administration announced earlier it would conduct an investigation into drug imports. That move is widely seen as a first step toward imposing new levies. Earnings and revenue both beat estimates for the quarter. Johnson & Johnson CFO Joe Wolk joined Bloomberg Open Interest to talk about how tariffs could hit the industry and the drug maker's bottom line.

Bloomberg videos, provided by MT Newswires

Latest news about Johnson & Johnson

Dec. 16	S&P Global Appoints Hubert Joly to the Board of Directors and Member of Audit and Compensation and Leadership Development Committees, Effective January 2, 2026	CI
Dec. 15	The Hain Celestial Group, Inc. Appoints Alison E. Lewis as President, Effective December 15, 2025	CI
Dec. 15	FDA awards national priority voucher to teclistamab	RE
Dec. 15	Johnson & Johnson Remains Stable With Modest Growth Potential, BofA Says	MT
Dec. 15	US FDA grants priority voucher to J&J's blood cancer treatment	RE
Dec. 15	Santa Ghosted Wall Street
Dec. 15	Johnson & Johnson's Prostate Cancer Therapy Application Approved by US FDA	MT
Dec. 15	Johnson & Johnson Hit With $40 Million Talc-Lawsuit Verdict by the Los Angeles Superior Court	MT
Dec. 12	Johnson & Johnson Announces U.S. Food and Drug Administration Approves AKEEGA as the First Precision Therapy for BRCA2-Mutated Metastatic Castration-sensitive Prostate Cancer with 54% Reduction in Disease Prostate Cancer with 54% reduction in Disease Prostate Cancer	CI
Dec. 15	Jury orders Johnson & Johnson to pay $40 million to two women in latest talc trial	RE
Dec. 12	U.S. FDA approves AKEEGA therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer	RE
Dec. 12	California jury orders Johnson & Johnson to pay $40 million after finding company failed to warn consumers about baby powder cancer risk	RE
Dec. 12	California jury orders Johnson & Johnson to pay $40 million after finding company failed to warn consumers about baby powder cancer risk	RE
Dec. 12	FDA approves niraparib and abiraterone acetate plus prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer	RE
Dec. 12	Blencowe hits high grades; Roquefort advances trial	AN
Dec. 12	Wells Fargo Adjusts Price Target on Johnson & Johnson to $230 From $212, Maintains Overweight Rating	MT
Dec. 12	Morgan Stanley Adjusts PT on Johnson & Johnson to $197 From $190, Maintains Equalweight Rating	MT
Dec. 12	Alzheimer's drug hunt learns from cancer fight's multi-target playbook	RE
Dec. 12	Roquefort Therapeutics plc Provides Update on Clinical Stage Progress	CI
Dec. 11	Sector Update: Health Care Stocks Advance Late Afternoon	MT
Dec. 11	Sector Update: Health Care Stocks Rise Thursday Afternoon	MT
Dec. 11	Johnson & Johnson Positioned for Growth on Multiple MedTech and Immunology Catalysts, RBC Says	MT
Dec. 11	RBC Raises Price Target on Johnson & Johnson to $230 From $209, Keeps Outperform Rating	MT
Dec. 11	Citigroup Adjusts Price Target on Johnson & Johnson to $232 From $215, Maintains Buy Rating	MT
Dec. 10	Legend Biotech's Stock Weakness After Rival Treatment Update 'Overdone,' RBC Says	MT

Chart Johnson & Johnson

Duration

Period

JNJ: Dynamic Chart

Company Profile

Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (64.1%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (35.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; At the end of 2024, Johnson & Johnson has 64 manufacturing facilities located in the United States (23), North America (7), Europe (21), Africa and Asia/Pacific (13). The United States accounts for 56.6% of net sales.

Employees

138,100

Sector

Pharmaceuticals

Calendar

Jan. 12 - J.P. Morgan Healthcare Conference

More about the company